Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.
You may also be interested in...
Battered XenoPort Holds On For April PDUFA Date For Horizant
XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.
Battered XenoPort Holds On For April PDUFA Date For Horizant
XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.
FDA Plows Out: Telecommuting Triumphs As Blizzard Puts A Hole In CDER's Roof
PDUFA user fee dates could slip by as much as five business days because of the blizzards that shut down the federal government in Washington, D.C., Feb. 8-11